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OBJECTIVE — In adults, higher fasting plasma glucose (FPG) levels, even within the nor-
moglycemic range, are associated with increased diabetes risk. This investigation tested the
hypothesis that -cell function relative to insulin sensitivity decreases with increasing FPG in
youth.
RESEARCH DESIGN AND METHODS — A total of 223 youth with FPG 126 mg/dl
underwent evaluation of ﬁrst- and second-phase insulin secretion during a 2-h hyperglycemic
(225mg/dl)clamp,insulinsensitivityduringa3-hhyperinsulinemic-euglycemicclamp,body
composition, and abdominal adiposity with dual-energy X-ray absorptiometry and computed
tomographic scan. -Cell function relative to insulin sensitivity was calculated as the product of
ﬁrst-phaseinsulinandinsulinsensitivity,i.e.,glucosedispositionindex(GDI).Thesubjectswere
divided into three FPG categories: 90, 90–100, and 100–126 mg/dl.
RESULTS — GDI decreased signiﬁcantly across the three categories as FPG increased
(1,086  192 vs. 814  67 and 454  57 mg/kg/min, P  0.002). This decline remained
signiﬁcant after adjustment for race, sex, BMI, and percent body fat or visceral fat. Within each
FPG category, GDI declined with increasing BMI percentiles.
CONCLUSIONS — The impairment in -cell function relative to insulin sensitivity is ap-
parent even within the nondiabetic FPG range in children. At the current cutoff of 100 mg/dl for
impaired fasting glucose (IFG), there is an 49% decline in the GDI independent of obesity and
race. This observation may reﬂect a heightened risk of -cell dysfunction and progression to
diabetes in these children. Considering the near doubling of IFG prevalence among youth
between National Health and Nutrition Examination Survey 1999–2000 and 2005–2006, our
ﬁndings have important public health implications.
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H
igher fasting plasma glucose (FPG)
levels within the currently accepted
normoglycemic range seem to have
animpactondiabetesriskinadults(1–3).
FPG levels 125 mg/dl indicate a provi-
sional diagnosis of diabetes (4). FPG lev-
els below this cutoff but above normal
increase the risk of developing diabetes
(5) and are associated with a higher car-
diovascular disease risk (6,7). The Amer-
ican Diabetes Association classiﬁes this
intermediate state of FPG as impaired
fasting glucose (IFG) (4) and initially de-
ﬁned it as fasting glucose of 110–125
mg/dl (8), which was lowered to 100
mg/dl in 2003 to better identify subjects
at risk of diabetes development (9). Sev-
eralstudiesinadultssuggestedthatfuture
diabetes risk increases continually with
increasing FPG even below this lower
cutofffornormoglycemia(1,2).Inadults,
fasting glucose levels of 90–94 mg/dl
conferred a 49% greater risk of develop-
ing diabetes compared with levels 85
mg/dl (2). FPG levels in the top quintiles
(95–99 mg/dl) of the normoglycemic
range constituted an independent risk
factor for type 2 diabetes among young
men in the Israeli army after adjustment
for several risk factors (1). In a Mauritius
population-based study, parameters re-
lated to diabetes and cardiovascular dis-
ease such as higher BMI, cholesterol,
triglycerides, and hypertension were pos-
itively correlated with higher FPG values
in an approximately linear relationship
(3). In addition, a meta-analysis of pro-
spective studies showed a continuous re-
lationship between baseline fasting
glucose and subsequent cardiovascular
risk (10). These observations raise a fun-
damental question: are insulin secretion
andsensitivityimpairedathigherlevelsof
FPG but within the normal range? Few
studies in adults have investigated this
question, and results are conﬂicting (11–
13). However, none of these studies used
robust methodologies of assessing in vivo
insulin secretion and sensitivity to derive
a glucose disposition index (GDI), which
is accepted to be the best indicator of
-cell dysfunction (14). Currently there
are no published data assessing the rela-
tionship between high-normal fasting
glucose levels and insulin sensitivity and
secretion in children. The pre-diabetes
cutoff levels for FPG in pediatrics are
based on adult data and not on data gen-
erated in pediatric populations.
In this study, we investigated the re-
lationship between levels of fasting glu-
cose and insulin secretion relative to
insulin sensitivity, i.e., GDI, in children.
Based on adult observations we hypothe-
sized that -cell function relative to
insulin sensitivity decreases as FPG con-
centrations increase within the currently
accepted nondiabetic range in children.
RESEARCH DESIGN AND
METHODS— Youth 8–19 years old
with FPG concentrations 126 mg/dl
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Institutes of Health–funded studies to
evaluate childhood metabolic markers of
adult morbidity were identiﬁed. We in-
cluded 223 participants who had under-
gone both a hyperglycemic clamp and a
hyperinsulinemic-euglycemicclamp,181
of whom were reported previously in a
differentcontext(15).Participantsforour
studiesarerecruitedfromthecommunity
through local newspaper advertisements,
ﬂyers posted at various locations includ-
ing public bus routes, children’s recre-
ational centers, the medical campus, and
the Children’s Hospital of Pittsburgh as
before (15). A complete medical history
was obtained from each participant, and
all underwent a thorough physical exam-
inationincludingpubertalTannerstaging
by a pediatric endocrinologist and/or a
certiﬁed nurse practitioner. For girls,
Tanner stage was determined based on
pubic hair and breast development and
for boys it was based on pubic hair and
testicular volume, using the Prader or-
chidometer. In case of a discrepancy be-
tween pubic hair stage (which is mainly
driven by adrenarche) and breast devel-
opment in girls or testicular volume in
boys (which are driven by gonadal activa-
tion of puberty), the latter staging was as-
signed. All studies were approved by the
Institutional Review Board of the Univer-
sity of Pittsburgh. Informed consent and
assent were obtained from each partici-
pant and their legal guardians.
Clamp studies
Participants were admitted twice within a
1- to 4-week period to the Pediatric Clin-
icalandTranslationalResearchCenterthe
day before the clamp studies, once for a
hyperinsulinemic-euglycemic clamp and
then for a hyperglycemic clamp in ran-
dom order. Each clamp evaluation was
performed after a 10- to 12-h overnight
fast. A fasting blood sample was obtained
for total cholesterol, HDL, LDL, VLDL,
and triglyceride measurements. For each
clamp study, two intravenous catheters
were inserted after the skin and subcuta-
neous tissues were anesthetized with
EMLAcream(AstraPharmaceuticalProd-
ucts, West Borough, MA). One catheter
was placed in a vein on the forearm for
administration of glucose and insulin; the
secondcatheterwasplacedinaveininthe
dorsum of the contralateral heated hand
for sampling of arterialized venous blood
as reported (16).
Hyperinsulinemic-euglycemic clamp
A 3-h hyperinsulinemic-euglycemic
clamp was performed with plasma glu-
coseclampedat100mg/dlwithavariable
rate infusion of 20% dextrose based on
arterialized plasma glucose determina-
tions every 5 min as described before
(16). Continuous indirect calorimetry by
a ventilated hood system (Deltatrac Met-
abolic Monitor; Sensormedics, Anaheim,
CA) was performed to measure CO2 pro-
duction, O2 consumption, and respira-
toryquotientfor30minatbaselineandat
the end of the clamp (16).
Hyperglycemic clamp
First- and second-phase insulin secretion
wereassessedduringa2-hhyperglycemic
clamp (225 mg/dl) as described before
(16). Glucose and insulin concentrations
were measured every 2.5 min (at 2.5, 5,
7.5, 10, and 12.5 min, ﬁrst phase) and
thereafter every 5 min for glucose and ev-
ery 15 min for insulin.
Body composition
Body composition was determined by
dual energy X-ray absorptiometry. Sub-
cutaneous abdominal adipose tissue
(SAT) and visceral adipose tissue (VAT)
wereexaminedbyasingleslicecomputed
tomographic scan at L4–L5 as described
before (16).
Biochemical measurements
Plasma glucose was measured with a glu-
cose analyzer (YSI, Yellow Springs, OH),
and insulin was measured by radio-
immunoassay as before (16). A1C was
measured by high-performance liquid
chromatography (Tosoh Medics), and
lipids were measured using the standards
of the Centers for Disease Control and
Prevention (16).
Calculations
Insulin-stimulatedRdwascalculatedduring
thelast30minofthe3-hhyperinsulinemic-
euglycemic clamp to be equal to the rate
of exogenous glucose infusion. Periph-
eral insulin sensitivity was calculated
by dividing the Rd by the steady-state
clampinsulinlevelasreportedbyus(17).
Insulin-stimulated carbohydrate and fat
oxidation rates were calculated according
to the formulas of Frayn (18) from the
indirect calorimetry data. Nonoxidative
glucose disposal was estimated by sub-
tractingtherateofglucoseoxidationfrom
the total Rd. During the hyperglycemic
clamp,theﬁrst-andsecond-phaseinsulin
concentrations were calculated as
describedpreviously(16).GDIwascalcu-
lated as the product of insulin sensitiv-
ity  ﬁrst-phase insulin (17).
Statistical analysis
Differences in continuous variables
among the three groups were tested with
either a one-way ANOVA or the nonpara-
metric Kruskall-Wallis test, based on the
nonviolation of statistical assumptions.
Differences in categorical variables were
tested using the 
2 test or the Fisher exact
test. The univariate general linear model
(ANCOVA) was used to compare the
main outcome measures among the three
categories of FPG. Each outcome mea-
sure/dependent variable was entered sep-
arately into the model, with FPG category
as the ﬁxed factor. Potential confounders
adjusted for were entered as covariates in
each model and are speciﬁed with the re-
ported results. All statistical assumptions
were met. Data are presented as means 
SEM unless otherwise indicated. Statisti-
cal signiﬁcance was set at P  0.05. All
statistical analyses were performed using
SPSS software (SPSS, Chicago, IL).
RESULTS— The group consisted of
86 boys and 137 girls (38.6 and 61.4%,
respectively). Ninety-eight subjects
(43.9%) self-identiﬁed as African Ameri-
cans, 120 (53.8%) as Caucasians, and 5
(2.2%) as biracial. Of the female subjects,
52 had polycystic ovary syndrome
(PCOS) (Table 1). None of the partici-
pants, including the girls with PCOS,
were taking medications that affected
blood glucose metabolism.
The study participants were divided
into three groups based on the mean of
four FPG levels obtained 10 min apart
before the start of the hyperinsuline-
mic-euglycemicclamp:90mg/dl(n 
40), 90–100 mg/dl (n  136),
and 100–126 mg/dl (n  47).
There was 85% concordance between
the FPG levels obtained at the time
of the hyperinsulinemic-euglycemic
clampandthemeanofthreeFPGlevels,
15 min apart, at the time of the hyper-
glycemic clamp. Age, sex, race, and
Tanner stage distributions were similar
among the three groups (Table 1). The
numbers of girls with PCOS were simi-
lar in the three FPG groups: 12 (30%),
29 (21.3%), and 11 (23.4%) (P  0.5),
respectively. BMI tended to be higher
with higher FPG categories (P  0.07);
this difference became signiﬁcant after
adjustment for race, sex, and age
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were signiﬁcantly higher with higher
FPG categories. Fat mass tended to be
higher with higher FPG categories (P 
0.07). This difference reached signiﬁ-
canceafteradjustmentforrace,age,and
sex (ANCOVA; P  0.019). Waist cir-
cumference, waist circumference per-
centiles, VAT, SAT, and percent body
fat were not signiﬁcantly different
among the three groups (Table 1) and
remained nonsigniﬁcant after adjust-
ment (ANCOVA) for age, race, and sex,
waist circumference (P  0.21), VAT
(P  0.49), and SAT (P  0.11) but
became signiﬁcant for percent body fat
(P  0.04).
Fasting metabolic proﬁle
Besides glucose, there were no signiﬁcant
differences among the groups except for
fasting insulin levels (Table 1). However,
after adjustment for BMI or BMI percent
the difference disappeared (P  0.17 and
0.27, respectively).
In vivo insulin sensitivity and
insulin secretion
Insulin-stimulated total, oxidative, and
nonoxidative glucose disposal was signif-
icantly lower in the highest fasting glu-
cose category (Fig. 1A). Similarly, insulin
sensitivity was signiﬁcantly lower in the
categories with higher FPG (Fig. 1B). The
difference in insulin sensitivity did not
persistafteradjustmentforBMI(P0.3).
First- and second-phase insulin secre-
tion were not signiﬁcantly different
among the three categories of FPG, but
becamesigniﬁcantlylowerwithincreas-
ing FPG after adjustment for BMI (Fig.
1C and D).
GDI
The GDI decreased signiﬁcantly with in-
creasing FPG categories (Fig. 2A). Using
ANCOVA with BMI, VAT, age, race, sex,
and Tanner stage as the covariates, the
difference in GDI remained signiﬁcant
(P  0.001). Likewise, the difference re-
mained signiﬁcant when fat mass was
addedtothemodel(P0.002).Further-
more, within each glucose category par-
ticipants with BMI 95th percentile had
signiﬁcantly lower GDI than those with
BMI 85th percentile (Fig. 2B). In addi-
tion, GDI remained signiﬁcantly lower in
the higher categories of FPG when the
subjects with PCOS were excluded from
theanalysis.Whenthedatawereanalyzed
separatelyforprepubertal(TannerstageI,
n43)andpubertal(TannerstagesII–V,
n  180) subjects, GDI in the pubertal
group but not in the prepubertal group
was consistent with the whole-group
analysis.Amongpubertalyouth,GDIwas
lowest in the higher FPG category
(383.4  40.6 vs. 743.6  77.2 and
712.5  115.9 mg/kg/min, P  0.02, in
FPG100–126mg/dl[n43],90–
100 mg/dl [n  110], and 90 mg/dl
[n  26], respectively). This trend in pre-
pubertal children did not reach signiﬁ-
cance; however, the numbers of subjects
werelimited,especiallyinthehighestglu-
cosecategory(1779.8459.4,1121.4
106.1, and 1216.7  359.7 mg/kg/min,
P  0.2, in FPG 90 mg/dl [n  14],
90–100 mg/dl [n  25], and 100–
126 mg/dl [n  4], respectively).
CONCLUSIONS — In the present
study, we investigated in children the rela-
tionship between -cell function relative to
insulin sensitivity and fasting plasma glu-
cose levels across the normoglycemic and
IFG ranges. Our ﬁndings demonstrate that
in the IFG category, 100–126 mg/dl,
Table 1—Physical and metabolic characteristics of participants categorized according to
fasting glucose levels
FPG
ANOVA P
value 90 mg/dl
90–100
mg/dl
100–126
mg/dl
n 40 136 47
Age (years) 12.8  0.4 12.9  0.2 13.2  0.3 0.69
Sex* 0.18*
Male 11 (27.5) 53 (39) 22 (47)
Female 29 (72.5) 83 (61) 25 (53)
Race* 0.98*
African American 16 (40) 60 (44) 22 (47)
Caucasian 23 (57.5) 73 (54) 24 (51)
Biracial 1 (2.5) 3 (2.2) 1 (2)
Tanner stage* 0.052*
I 14 (35) 25 (18.4) 4 (8.5)
II 3 (7.5) 19 (14) 4 (8.5)
III 6 (15) 28 (20.6) 10 (21)
IV 4 (10) 19 (14) 13 (28)
V 13 (32.5) 45 (33) 16 (34)
Weight (kg) 68.2  5.7 73.0  2.7 82.9  3.9 0.08
Height (cm) 154.2  2.2 156.4  1.1 160.5  1.6 0.07
BMI (kg/m
2) 27.1  1.7 28.6  0.8 31.6  1.2 0.07
BMI % 76.2  4.4 82.2  2.1 92.5  2.3 0.005
Fat mass (kg) 24.1  3.2 26.1  1.6 32.2  2.4 0.07
% body fat 33.6  2.5 34.0  1.2 38.0  1.8 0.21
Waist circumference (cm) 85.9  5.0 86.1  2.4 94.7  3.2 0.14
Waist circumference
percentile
0.16*
75th 12 (40) 34 (37.8) 7 (20)
75th–90th 6 (20) 12 (13.3) 4 (11.4)
90th 12 (40) 44 (48.9) 24 (68.6)
SAT (cm
2) 311.7  44.3 337.1  22.3 398.0  32.8 0.25
VAT (cm
2) 49.8  6.7 48.5  3.6 56.9  5.1 0.47
Glucose (mg/dl) 87.6  0.3 94.9  0.2 105.0  0.6 0.001
Insulin (	U/ml) 28.1  4.2 30.5  1.7 40.2  3.6 0.02
A1C (%) 5.3  0.08 5.3  0.04 5.4  0.07 0.56
Cholesterol (mg/dl) 160.8  5.7 164.8  2.4 165.3  5.2 0.75
LDL (mg/dl) 90.1  5.7 98.6  2.1 100.4  5.2 0.2
HDL (mg/dl) 47.0  1.7 45.8  0.9 42.4  1.8 0.11
Triglycerides (mg/dl) 116.9  11.5 102.4  4.6 114.8  10.8 0.29
VLDL (mg/dl) 23.4  2.3 20.3  0.9 21.6  1.8 0.3
Data are unadjusted means  SEM or n (%). Ten subjects with FPG 90 mg/dl, 46 subjects with FPG
90–100 mg/dl, and 12 subjects with FPG 100–126 mg/dl did not have waist circumference data
because this measurement was implemented late in the course of the grant project. *
2 analysis.
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-cell function relative to insulin sensitivity
independent of obesity and race, whereas a
decline of 23% is present in the 90–
100 mg/dl category compared with that
in the lower FPG of 90 mg/dl. Further-
more, within each fasting glucose category
BMI 95th percentile is associated with an
additional decline of 50–70% in GDI.
Under normal physiologic conditions glu-
coseconcentrationsremainwithinanarrow
rangeinthefastingaswellasinthefedstate.
Thistightregulationismaintainedbyadel-
icate balance between insulin sensitivity
and secretion (19). A hyperbolic relation-
ship governs this balance, such that the
product of insulin sensitivity and insulin
secretion is a constant in any given individ-
ual (20). This product is known as the GDI
and is a more accurate reﬂection of -cell
function than absolute insulin secretion,
because it normalizes the pancreatic re-
sponse to the degree of insulin sensitivity
(21). In this study, insulin sensitivity de-
creased as FPG increased even within the
normal range, but insulin secretion did not
increase sufﬁciently to maintain the GDI.
These ﬁndings suggest that the impair-
ments in insulin sensitivity and -cell re-
sponseleadingtodiabetesmaybeevidentat
plasma glucose levels well within the nor-
moglycemic range.
Our ﬁndings with respect to insulin
sensitivity are consistent with data from the
adult literature, which have used different
FPGcategories.Weelectedtocategorizethe
study participants according to the above
FPGlevelstoshowrelevancewithrespectto
clinically recommended diagnostic catego-
ries. In a recent large study of 6,414 adult
Finnish men, insulin sensitivity derived
from an oral glucose tolerance test (OGTT)
(Matsuda index) was 17% lower within the
normal range of FPG 90–97.2 mg/dl com-
pared with that for FPG 90 mg/dl inde-
pendent of obesity (13). Likewise, another
study reported decreased insulin sensitivity
in the highest quartile of FPG (94–110 mg/
dl)among148postmenopausalwomenus-
ing a 2-h hyperinsulinemic-euglycemic
clamp (11). An earlier study in adults re-
ported a 20% decline in insulin sensitivity,
measured by the euglycemic clamp, among
62 adults with normal glucose tolerance
and a fasting glucose ranging from 84.6 to
108mg/dl(22).Ourdatarevealedadecline
in total, oxidative, and nonoxidative insu-
lin-stimulated glucose disposal and a de-
cline in in vivo clamp-measured insulin
sensitivityasFPGincreased.Thisdeclinein
Figure 1—Insulin-stimulated glucose disposal (total, oxidative, and nonoxidative) (A) and insulin sensitivity (B) during the hyperinsulinemic-
euglycemic clamp and ﬁrst- and second-phase insulin levels (C and D) during the hyperglycemic clamp in youth with FPG 90 mg/dl ( ),
90–100 mg/dl (u), and 100–126 mg/dl (o). Data represent the estimated marginal means from the ANCOVA model corrected for BMI. P
values unadjusted and adjusted for BMI are shown.
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crease in BMI.
For insulin secretion and FPG, stud-
ies from the adult literature have conﬂict-
ing results. A Finnish study reported only
a slight decline in early-phase insulin se-
cretion during the OGTT in the normo-
glycemic range among adult men (13).
Another study in adult men, using the in-
travenousglucosetolerancetestshoweda
marked decline in ﬁrst-phase insulin se-
cretionatFPGlevelsbetween90and97.2
mg/dlandalossofﬁrst-phase-cellfunc-
tion at a rate of 3.8 to 4.5% per 1.8 mg/dl
increase in FPG. In the same study a de-
cline in late-phase insulin secretion was
detected at FPG levels 108 mg/dl (12).
On the other hand, a study in postmeno-
pausal women reported an increase in
baseline and maximal arginine-induced
insulin secretion in the highest quartiles
of FPG (94–110 mg/dl) (11). An earlier
study in adults of both sexes, using the
C-peptide deconvolution during the
OGTT for -cell function, reported a de-
cline in -cell glucose sensitivity by 50–
70% within the normal glucose tolerance
range (22). However, the study included
subjects with impaired glucose tolerance
and with overt diabetes and reported a
detectable decline in GDI only in the sub-
jects with type 2 diabetes (22). In our
young subjects, there was no signiﬁcant
difference in absolute ﬁrst- and second-
phase insulin secretion during the hyper-
glycemic clamp as FPG increased. This
ﬁnding could potentially be explained by
the younger age of our participants,
which might have precluded the manifes-
tation of an overt decline in the absolute
-cellresponseduringthehyperglycemic
clamp. However, when insulin secretion
was expressed relative to insulin sensitiv-
ity (GDI), the impairment in -cell func-
tion and insulin secretion became
apparent as FPG levels increased within
the normal and IFG ranges. Use of
ANCOVA for age, Tanner stage, sex, and
race did not alter this observation. The
decline in GDI was signiﬁcant in pubertal
youth but not in prepubertal youth when
the data were analyzed separately. How-
ever, the number of prepubertal children
in the IFG category was very limited (n 
4) and did not allow for any statistical
signiﬁcance, especially because the study
was not designed to test this. It would be
interesting however, to test whether the
observation of declining GDI with in-
creasing FPG holds true in a larger group
of prepubertal children.
Two large longitudinal studies in
adults, one in the U.S. (2) and one in Is-
rael(1),havereportedanincreasedriskof
diabetes incidence as FPG increases
within the normoglycemic range. This
riskwaspotentiatedbyanincreaseinBMI
(2).Althoughourstudyiscross-sectional,
the ﬁndings of 23% lower GDI with
higher FPG in the normoglycemic range
and 49% in the IFG range is in concor-
dance with the increased risk of type 2
diabetes development in the aforemen-
tioned studies. Considering the near dou-
bling of IFG prevalence among youth
between the National Health and Nutri-
tion Examination Survey (NHANES)
1999–2000 (7%) and 2005–2006
(13.1%) (23), our current ﬁndings bear
important public health implications for
the 4,381,711 U.S. adolescents with
IFG.Inadults22%ofsubjectswithIFG
progresstodiabetesoveranobservational
period of 3–5 years (3). There are no lon-
gitudinal studies assessing the progres-
sion from IFG to overt diabetes in
children and adolescents. However, if the
conversionrateissimilartothatinadults,
our ﬁndings together with the increased
prevalence of IFG paint a bleak picture
for the future rates of diabetes among
older adolescents and young adults. Fur-
thermore, in our study GDI was signiﬁ-
cantlylower(50–70%)inchildrenwith
BMI 95th percentile versus those with
BMI 85th percentile within each cate-
gory of FPG (Fig. 2B). The reported
NHANES 2003–2006 prevalence rate of
children2–19yearswithBMI95thper-
centile is 16.3% (24), which translates to
5 million children in the overweight
category. Recent reports show that young
Figure 2—A: GDI (milligrams per kilogram per minute) in youth with FPG 90 mg/dl ( ),
90–100 mg/dl (u), and 100–126 mg/dl (o). Data represent the estimated marginal
means from the ANCOVA model. ‡Covariates appearing in the model are age, sex, race, Tanner
stage, BMI, and VAT.
aP  0.002 when fat mass is added as a covariate to the model;
bP  0.003
when fat mass, lean mass, and height are added as covariates to the model. *P represents post hoc
Bonferroni correction. B: GDI (milligrams per kilogram per minute) in youth with FPG 90
mg/dl, 90–100 mg/dl, and 100–126 mg/dl according to BMI 85th percentile ( ),
between the 85th and 95th percentiles ( ), and 95th percentile (f). P represents ANOVA.
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5 years had an increased odds ratio of 2.6
of having diabetes by age 21 years (25).
Our ﬁndings of 50% lower GDI in
obese youths, even within the normogly-
cemic range suggest that within the same
fastingglucosecategoryobeseindividuals
have twice the impairment in -cell func-
tion potentially increasing their risk of fu-
ture diabetes. Of interest is the 8.8%
prevalence of IFG among the participants
with BMI 85th percentile in our study.
Our subjects were recruited from the
community with no speciﬁc targeting for
offspringofparentswithdiabetesorhigh-
risk children with abnormal fasting glu-
coselevels.Furthermore,theyweretested
inaPediatricClinicalResearchCenterun-
der very controlled conditions with close
supervision. Considering the latter and
also considering that the current rate of
IFG is lower than that observed in other
studies (23), we trust that these are rep-
resentative data. One limitation of our
study is the lack of oral glucose tolerance
data, mainly in normal-weight youth.
Some of our subjects with or without IFG
could have impaired glucose tolerance
and represent a different category with
further impairment in GDI. However, all
oftheparticipantshadnormalA1Clevels.
Another limitation is the discrepancy in
the sample sizes in the different FPG cat-
egories.Therelativelysmallernumbersin
the FPG 90 mg/dl category may have
precluded detection of signiﬁcant differ-
ences in GDI between subjects in this
group and those in the FPG 90–100
mg/dl category.
In summary, our ﬁndings demon-
strate that the impairment in -cell func-
tion and insulin secretion relative to
insulin sensitivity is already evident at
fasting plasma glucose levels well within
the normoglycemic range in children.
This stepwise decline in -cell function
with increasing FPG seems to be potenti-
atedbyhigherBMI,aﬁndingofparticular
importance in the context of the ever-
escalatingtrajectoryinchildhoodobesity.
Itremainstobeseeninlongitudinalstud-
ies whether those children with higher
FPG levels will be at higher risk to de-
velop overt diabetes.
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